A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT02131064 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

444

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Trastuzumab Emtansine

Sponsor

Hoffmann-La Roche